Reviva Pharmaceuticals (RVPH) Lytham Partners 2025 Investor Healthcare Summit summary

Strategic focus and pipeline development

• Emphasis on developing next-generation therapeutics for diseases with narrow targets, with a lead candidate in phase III and NDA submission planned for early 2026.

• Two in-house discovered molecules are in development, with multiple clinical catalysts expected in the next 12–18 months.

• Brilaroxazine, the lead candidate, is being developed for schizophrenia and potentially other neuropsychiatric and inflammatory conditions.

• The company aims to address significant unmet needs in schizophrenia, especially treatment-refractory patients and negative symptoms.

• Plans include a second confirmatory phase III study starting soon, with full long-term safety data expected in March.

Clinical trial results and efficacy

• Brilaroxazine demonstrated robust efficacy in both phase II and III trials, with a 10-point separation from placebo on the primary endpoint.

• Statistically significant improvements were observed in negative symptoms, agitation, and functional outcomes, with early onset of action.

• Compliance rates were high, with a discontinuation rate of 16%, lower than placebo and historical comparators.

• The drug showed strong anti-inflammatory effects, including significant reductions in IL-8 and prolactin, and improvement in BDNF.

• Long-term safety data confirmed sustained efficacy and a favorable safety profile over one year.

Differentiation and safety profile

• Brilaroxazine is differentiated by its broad spectrum efficacy, superior tolerability, and low rates of adverse events.

• Selectivity for target receptors and minimal off-target activity contribute to its safety and tolerability.

• The drug is unlikely to cause drug-drug interactions, supporting long-term adherence.

• Digital biomarker analysis showed even greater efficacy in patients with high negative symptoms.

• Side effects were minimal, with somnolence and headache being the most common, and overall profile comparable to placebo.